admin | April 30, 2021
June 23, 2014
The Stem Cell Physiopathology group at the CNIC (the Spanish National Cardiovascular Research Center), led by Dr. Simón Méndez–Ferrer has shown that the micro-environment of the bone marrow is a good target for therapeutic options for people with myeloproliferative neoplasms. Click here for the letter, recently published in Nature, or click here for the press release from the group. This same group has been working on a possible treatment and are hoping to move into Phase II clinical trials in Europe.
To keep up with news on this and other MPN research breakthroughs click here.